Su Jin Ahn

Title: The Innovative Contributions of Su Jin Ahn

Introduction

Su Jin Ahn is a notable inventor based in South Korea. She has made significant strides in the field of biotechnology, particularly in the development of therapeutic agents. Her work focuses on improving the pharmacological activity and stability of fusion proteins.

Latest Patents

Su Jin Ahn is credited with a patent titled "Fusion Protein Comprising CCL3 Variant and Use Thereof." This invention provides a fusion protein that includes a CCL3 variant with enhanced in vivo persistency and protein stability. The patent outlines the use of this fusion protein as a therapeutic agent for conditions such as lymphopenia, cancer, or infection. The CCL3 variant is characterized by the deletion of an N-terminal amino acid from the wild-type CCL3a or CCL3ß, along with a specific amino acid substitution.

Career Highlights

Throughout her career, Su Jin Ahn has demonstrated a commitment to advancing medical science through her innovative research. Her work has the potential to impact the treatment of various diseases, showcasing her expertise in the field of protein engineering.

Collaborations

Su Jin Ahn has collaborated with notable colleagues, including Su Youn Nam and Jong Gyun Kim. These partnerships have contributed to the development of her groundbreaking research and innovations.

Conclusion

Su Jin Ahn's contributions to biotechnology and her innovative approach to developing therapeutic agents highlight her importance in the field. Her work continues to pave the way for advancements in medical treatments.